21 June 2013

Profitability at Peak; Revenue growth intact on Capex Vardhman Textiles :: Karvy

Profitability at Peak; Revenue growth intact on Capex
Vardhman Textiles (VTEX) sales, EBITDA and net income grew 18%, 51%
and 103% YoY respectively during Q4FY13 while sequential growth was
reported at 5%, 19% and 38% respectively.
The Company’s top‐line grew 18.1% YoY to Rs. 11,463 mn (our expectations
Rs. 11,039 mn) during Q4FY13, while sequential growth was registered at
4.9%. Yarn sales grew 24.2% YoY to Rs. 9,933 mn, while revenue from fabric
grew 30.8% YoY to Rs. 4,046 mn during the quarter.

A closer look at Raw Material trends and impact on staples :: JPMorgan

 Raw material price trends. Most of the raw materials that we follow
have been either stable or moderating over 3m/6m/12m period. Palm oil
and Crude, however, have started to inch up over the past month. Agri
commodities like sugar and wheat have been benign. On a y/y basis,
most commodities (wheat being an exception) are either stable or lower.

Dipping into profit pools :: Business Line

Business groups, redeploy cash generated, offer high returns, into not as productive.
India is popular for its large business groups and conglomerates with many subsidiaries/associates operating under one umbrella. These group companies are either in the same sector or in widely different ones.
Now, add to this the fact that certain industries generate better return on capital (ROCE) compared to others, due to inherent industry characteristics. For example, IT services is more profitable than steel manufacturing
Also, within a particular industry, some parts of the value chain are more profitable compared to others, due to ‘profit pools’. For instance, within the automotive industry, control cables manufacturing is more profitable than seat manufacturing.

Buy today, sell tomorrow not feasible :: Business Line

One of the questions that has been often asked at the investor seminars is whether the shares bought today can be sold tomorrow. Prima facie, the answer to this question is a big No. They can not be. However, some stock brokers are offering the ‘buy-today-sell-tomorrow’ (BTST) facility to clients.
In order to understand the facility, it is imperative to first understand the T+2 settlement system. If an investor buys shares, say on a Monday, as per T+2 rule, the broker ought to credit the shares to the investor’s demat account by Wednesday, i.e., within two days of purchase. T+2 of course is a general rule. In view of practical difficulties faced by brokers, Securities and Exchange Board of India (SEBI) has granted them an additional day for the purpose.
Accordingly, the broker would have to credit the shares by end of business close on Thursday, rather than on Wednesday. Therefore, the T+2 system operates as T+3 in reality. However, there can be no complaints against this, since SEBI itself permits this. Coming back to the example quoted above, shares (purchased on Monday and) sold on Tuesday will, therefore, have to be delivered into the broker’s account by 4 p.m. on Wednesday evening by the investor. How can this happen?
Since shares purchased on Monday will only be credited to the investor’s demat account by Thursday. Also, shares which go into auction, will only be credited on Thursday. This example indicates that BTST is not feasible. Yet, some brokers are offering this facility, under which shares sold by the investor on Tuesday will be delivered to the broker on Thursday morning (before the ‘pay-in’ at 10.30 a.m.), instead of Wednesday evening.
However, as mentioned above, shares coming from auction will not be credited to investor’s demat account by Thursday morning. Since the investor can not give delivery of shares sold, these shares will in turn, go into auction. The investor has to carry this risk.
Obviously, not all the shares sold, but only the shortfall of shares coming from the ‘pay-out’, will go into auction.
These issues are mentioned in the trading account opening documents. However, most investors sign these documents, without bothering to read the entire terms and conditions.
In investor seminars, many investors state that they carry out purchase and sale transactions in shares in spite of not having demat accounts.
However, they are stating this out of ignorance, since their broker is also their DP (depository participant). Investors do not realise that they signed the demat account opening forms at the time of opening of trading account itself.
In any case, since they are receiving the demat account statement every month, they cannot say they do not have demat account.
In addition, investors invariably provide ‘power of attorney’ to the broker, to operate their demat account, but are not aware of the same. The tendency of signing documents without understanding contents or implications, is the root-cause of all this!

Pension plans: What’s your suit? :: Business Line


Recovery of Carbogen Amcis Dishman Pharma :Centrum

Recovery of Carbogen Amcis
Dishman Pharma’s (DPCL) revenues and EBIDTA for Q4FY13 were in line with our expectation. However, net profit was below our estmates. The company reported a decline of 0.5%YoY in revenues, 200bps in EBIDTA margin and 41%YoY in net profit. Revenues in CRAMS business declined by 0.5%YoY and in others by 2.9%YoY. DPCL incurred forex loss of Rs184mn which was included in other expenses. Tax rate was higher at 59.1% of PBT as it included deferred tax of Rs90mn. Carbogen Amcis (CA) reported a growth of 4% during the quarter and 20% in FY13. The management has given a guidance of 10-12% sales growth for FY14. We have a Buy rating for the scrip with a revised target price of Rs130 from Rs125 (based on 8x Sept’14 EPS of Rs16.3).

Flat sales growth: DPCL reported 0.5%YoY decline in revenues from Rs3.50bn to Rs3.48bn in Q4FY13. CRAMS revenues (63% of total) declined by 0.5%YoY from Rs2.20bn to Rs2.19bn. Its other businesses (37% of total) declined by 3%YoY from Rs1.30bn to Rs1.27bn. CA (34% of total) reported 4%YoY growth from Rs1.15bn to Rs1.20bn. Sales of Vitamin D3 business (15% of total) declined by 31%YoY from Rs751mn to Rs516mn as the Netherlands plant was under renovation.

Margin declines: DPCL’s EBIDTA margin for Q4FY13 dropped by 200bps from 23.5% to 21.5% due to the increase in personnel cost and other expenses. The company’s material cost declined by 690bps from 34.6% to 27.7% due to the change in product mix. Personnel cost increased by 270bps from 22.9% to 25.6% due to flat sales growth. Other expenses went up by 630bps from 18.9% to 25.2%.

BSE bulk deals 20/06/2013

Deal DateScrip CodeScrip NameClient NameDeal Type *QuantityPrice **
20/06/2013531866Aagam CapS R JUTE TRADERS PRIVATE LIMITEDS40,00082
20/06/2013531838AKL SOF INFOMAHESHCHANDRA CHUNILAL SHAHB2,237,238.44
20/06/2013512361Cupid TradesPRADEEP NARENDRA BHATTB19,812107.71
20/06/2013512361Cupid TradesSANJAY JETHALAL SONI (HUF)S9,000108.99
20/06/2013512361Cupid TradesVINAY H PARMARS11,600109.35
20/06/2013512361Cupid TradesVINAY H PARMARB11,600109.39
20/06/2013526821Daiichi Kark-$SHERNAZ FIROZE VAKILB207,00048
20/06/2013526821Daiichi Kark-$ASHOKKUMAR PARMARS194,60548
20/06/2013530945Gangotri IronPULIN INVESTMENTS PRIVATE LIMITEDS211,2703.24
20/06/2013512103Nidhi GranitesDEEPAK MAGANBHAI MAKWANAS6,30016.35
20/06/2013512103Nidhi GranitesRASIKLAL TALAKCHAND SHAHB3,80016.35
20/06/2013535647OTMLSHAH MANJULA SURESHB60,0006.56
20/06/2013535647OTMLBINA ATUL CHAUHANB60,0007.27
20/06/2013535647OTMLGUINESS SECURITIES LIMITEDS80,0007.33
20/06/2013535647OTMLCOMFORT INTECH LIMITEDS60,0007.72
20/06/2013532815SMS PharmaSMS PHARMACEUTICALS LIMITEDB102,918268.28
20/06/2013532815SMS PharmaS M S PHARMACEUTICALS LTDB72,055268.64
20/06/2013523878Total ExportsNANHI SINGHS40,90023.6
20/06/2013523878Total ExportsMAMTA SHARMAB40,90023.6
20/06/2013526441Vision CinemasRAJA MOHAMAD BIN MAIDENB200,0007.69
20/06/2013526441Vision CinemasSRINIVAS KARROTHIS185,0007.72
20/06/2013526441Vision CinemasSRINIVAS KARROTHIB179,6777.76

* B - Buy, S - Sell 
** = Weighted Average Trade Price / Trade Price 

NSE bulk deals 20-Jun-2013

DateSymbolSecurity NameClient NameBuy / SellQuantity TradedTrade Price /
Wght. Avg.
Price
Remarks
20-Jun-2013IVRCLINFRAIVRCL LimitedAMBIT SECURITIES BROKING PVT. LTD.BUY20,61,98415.54-
20-Jun-2013IVRCLINFRAIVRCL LimitedAMBIT SECURITIES BROKING PVT. LTD.SELL23,67,65815.59-
20-Jun-2013SMSPHARMASMS Pharmaceuticals LimitS M S PHARMACEUTICALS LIMITEDBUY85,810268.57-
20-Jun-2013SMSPHARMASMS Pharmaceuticals LimitSMS PHARMACEUTICALS LIMITEDBUY1,01,658268.36-